Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RESOLVE: A Phase 4, Open-label Study to Assess the Effect of Zunveyl on Safety and Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Adults With Mild to Moderate Alzheimer's Disease

NCT07633470 is registered in ClinicalTrials.gov with Alpha Cognition, Inc as lead sponsor.

NCT NCT07633470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07633470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RESOLVE: A Phase 4, Open-label Study to Assess the Effect of Zunveyl on Safety and Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Adults With Mild to Moderate Alzheimer's Disease
Lead sponsor
Alpha Cognition, Inc
Phase
Phase 4
Overall status
Recruiting
Start date
May 20, 2026
Completion date
April 30, 2027
Enrollment
150 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease